EPREX 2000 i.j./0.5 mL otopina za injekciju  u napunjenoj  štrcaljki Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

eprex 2000 i.j./0.5 ml otopina za injekciju u napunjenoj štrcaljki

inpharm co. d.o.o. banja luka - epoetin alfa - otopina za injekciju u napunjenoj štrcaljki - 2000 i.j./0.5 ml - 0,5 ml otopine za injekciju u napunjenoj štrcaljki sadrži: 2000 i.j epoetin alfa (humani rekombinantni eritropoetin)

Veklury Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

veklury

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Rozlytrek Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

rozlytrek

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastična sredstva - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.